Press - MIG Verwaltung EN

Börsen Zeitung, Finanzwelt, et al. - Tue, 27. April 2021

MIG reports best year in history

Several media report about the best year in history of MIG AG

Find out more

Abendzeitung - Mon, 26. April 2021

„Politics should create incentives“

Interview with Michael Motschmann, General Partner MIG AG, in „Abendzeitung“ about the future of German Biotech.

Tagesschau.de - Wed, 21. April 2021

Advantage for mRNA-Vaccines

"tagesschau.de" has a look at the future of vaccinations against Covid-19 with quotes of Dr. Matthias Kromayer, General Partner MIG AG.

Mehr erfahren

dpa - Tue, 20. April 2021

Biotech expects

German News Agency "dpa" reports about the Biotech Business in Germany with quotes of Michael Motschmann, General Partner MIG AG. Around 150 media published the article of dpa, among them ...

Mehr erfahren

Münchner Merkur - Wed, 14. April 2021

How to bring buildings into a computer

„Münchner Merkur“ portrays NavVis, a MIG-portfolio company.

Manager Magazin - Fri, 02. April 2021

Quantum Computing – it starts to be serious

A podcast of „Manager Magazin“ explains the state of the art of Quantum Computing and mentions MIG portfolio company IQM as a leading player and Michael Motschmann, General Partner MIG AG, as investor.

Find out more

Manager Magazin - Wed, 24. March 2021

Biontech Investors put on Quantum Computing

„Manager Magazin Online“ reports about the assignment of Helmut Jeggle as Member of the Supervisory Board of IQM. The article mentions MIG Fonds and Michael Motschmann, Gneneral Partner of MIG AG, as first investor of the Finnish-German Start-up in Quantum Computing.

Find out more

Süddeutsche Zeitung - Sun, 21. March 2021

Super Quanten

„Süddeutsche Zeitung“ reports about an innovative Quantum Computing Project of Leibnitz Rechenzentrum (LRZ) in Garching/Munich integrating IQM, a MIG portfolio company.

Find out more

VC Magazin - Sun, 21. March 2021

„Investors got their money seven times back“

Interview with Michael Motschmann, General Partner of MIG AG, in „VC-Magazin“ about the investment in BioNTech

Find out more

Manager Magazin - Sat, 20. March 2021

Going viral

In an article about the German Biotech Industry „Manager Magazin“ quotes Dr. Matthias Kromayer, General Partner of MIG AG.

DIE WELT - Thu, 18. March 2021

„What in Germany is possible“ and „The Heroes of the German Vaccine Fairy Tale“

„DIE WELT“ describes the development of MIG portfolio company BioNTech und the founders. The article refers to the role of Michael Motschmann and Dr. Matthias Kromayer, General Partner of MIG AG. Additionally an interview in „DIE WELT“ with Michael Motschmann.

Find out more

Handelsblatt - Wed, 17. March 2021

Six Start-ups are the German Hope in Quantum Computing

„Handelsblatt“ mentions IQM, a MIG portfolio company, as one of the leading German start-ups in Quantum Computing

Find out more

Börse Online - Thu, 11. March 2021

Success with molecules

In an article about Biotech IPOs in the US, „Börse Online“ quotes Dr. Matthias Kromayer, General Partner MIG AG.

Find out more

Wirtschaftswoche - Fri, 05. March 2021

The next enemy will be tougher

„Wirtschaftswoche“ explains the future of MIG portfolio company BioNTech with quotes of Michael Motschmann, General Partner MIG AG.

Find out more

Handelsblatt - Wed, 03. March 2021

Serious deficits

Angela Merkel and other heads of government claim a digital pact. Dr. Jan Goetz, CEO of MIG portfolio company IQM, calls for an European approach to Quantum Computing.

Find out more

BioCentury - Mon, 01. March 2021

The dark of COVID-19 brings promise to Germany´s biotech scene

Trade publication „BioCentury“ quotes Michael Motschmann, General Partner of MIG AG, in an article about the future of German Biotech industry.

Find out more

Tagesschau.de - Sat, 27. February 2021

Many ideas, little money

„tagesschau.de“ reports about investments in Biotech in Germany and quotes Michael Motschmann, General Partner MIG AG.

Find out more

Finanzwelt, VC Magazin - Wed, 24. February 2021

Next MIG Invest in Medical Technology

Several Trade Magazines report about MIGs investment in new portfolio company Creative Balloons.

Find out more

CHEManager - Wed, 17. February 2021

The Deals of German Biotech Investors

Trade Magazin „CHEManager“ reports about German Investors in Biotech, among them MIGs investments.

Find out more

Börsen Zeitung - Fri, 12. February 2021

Record return for MIG because of Biontech

„Börsen Zeitung“ interviews Michael Motschmann, General Partner of MIG AG, about new developments at MIG

Finanzwelt - Fri, 12. February 2021

MIG Fonds expand in the French Alps

„Finanzwelt“ reports about a new investment of MIG Fonds in Zadient Technologies.

Find out more

Financial Times, Reuters, Manager Magazine et al - Thu, 04. February 2021

BioNTech Fund (MIG) pays 600m Euro dividend on back of vaccine success

International and national media among them „Financial Times“ and „Reuters“ report about the record payment of MIG Fonds of 600m Euro to investors.

Find out more

Manager Magazin - Fri, 29. January 2021

Everything started with a dream

„Manager Magazin“ interviews Michael Motschmann, General Partner of MIG AG, and Co-Investors Thomas Strüngmann and Helmut Jeggle about their joint involvement at BioNTech SE.

Find out more

Handelsblatt - Thu, 14. January 2021

Exosceletts reduce sick days

„Handelsblatt“ reports about the technology of GBS, a start-up producing exosceletts; MIG Fonds invested recently.

Find out more

Frankfurter Allgemeine Zeitung - Sat, 09. January 2021

MIG - Press Review

2021

MIG reports best year in history

Several media report about the best year in history of MIG AG

„Politics should create incentives“

Interview with Michael Motschmann, General Partner MIG AG, in „Abendzeitung“ about the future of German Biotech.

Advantage for mRNA-Vaccines

"tagesschau.de" has a look at the future of vaccinations against Covid-19 with quotes of Dr. Matthias Kromayer, General Partner MIG AG.

Biotech expects

German News Agency "dpa" reports about the Biotech Business in Germany with quotes of Michael Motschmann, General Partner MIG AG. Around 150 media published the article of dpa, among them ...

„Münchner Merkur“ portrays NavVis, a MIG-portfolio company.

A podcast of „Manager Magazin“ explains the state of the art of Quantum Computing and mentions MIG portfolio company IQM as a leading player and Michael Motschmann, General Partner MIG AG, as investor.

„Manager Magazin Online“ reports about the assignment of Helmut Jeggle as Member of the Supervisory Board of IQM. The article mentions MIG Fonds and Michael Motschmann, Gneneral Partner of MIG AG, as first investor of the Finnish-German Start-up in Quantum Computing.

Super Quanten

„Süddeutsche Zeitung“ reports about an innovative Quantum Computing Project of Leibnitz Rechenzentrum (LRZ) in Garching/Munich integrating IQM, a MIG portfolio company.

„Investors got their money seven times back“

Interview with Michael Motschmann, General Partner of MIG AG, in „VC-Magazin“ about the investment in BioNTech

In an article about the German Biotech Industry „Manager Magazin“ quotes Dr. Matthias Kromayer, General Partner of MIG AG.

„What in Germany is possible“ and „The Heroes of the German Vaccine Fairy Tale“

„DIE WELT“ describes the development of MIG portfolio company BioNTech und the founders. The article refers to the role of Michael Motschmann and Dr. Matthias Kromayer, General Partner of MIG AG. Additionally an interview in „DIE WELT“ with Michael Motschmann.

Six Start-ups are the German Hope in Quantum Computing

„Handelsblatt“ mentions IQM, a MIG portfolio company, as one of the leading German start-ups in Quantum Computing

Success with molecules

In an article about Biotech IPOs in the US, „Börse Online“ quotes Dr. Matthias Kromayer, General Partner MIG AG.

The next enemy will be tougher

„Wirtschaftswoche“ explains the future of MIG portfolio company BioNTech with quotes of Michael Motschmann, General Partner MIG AG.

Serious deficits

Angela Merkel and other heads of government claim a digital pact. Dr. Jan Goetz, CEO of MIG portfolio company IQM, calls for an European approach to Quantum Computing.

The dark of COVID-19 brings promise to Germany´s biotech scene

Trade publication „BioCentury“ quotes Michael Motschmann, General Partner of MIG AG, in an article about the future of German Biotech industry.

Many ideas, little money

„tagesschau.de“ reports about investments in Biotech in Germany and quotes Michael Motschmann, General Partner MIG AG.

Next MIG Invest in Medical Technology

Several Trade Magazines report about MIGs investment in new portfolio company Creative Balloons.

The Deals of German Biotech Investors

Trade Magazin „CHEManager“ reports about German Investors in Biotech, among them MIGs investments.

Record return for MIG because of Biontech

„Börsen Zeitung“ interviews Michael Motschmann, General Partner of MIG AG, about new developments at MIG

MIG Fonds expand in the French Alps

„Finanzwelt“ reports about a new investment of MIG Fonds in Zadient Technologies.

BioNTech Fund (MIG) pays 600m Euro dividend on back of vaccine success

International and national media among them „Financial Times“ and „Reuters“ report about the record payment of MIG Fonds of 600m Euro to investors.

„Manager Magazin“ interviews Michael Motschmann, General Partner of MIG AG, and Co-Investors Thomas Strüngmann and Helmut Jeggle about their joint involvement at BioNTech SE.

Exosceletts reduce sick days

„Handelsblatt“ reports about the technology of GBS, a start-up producing exosceletts; MIG Fonds invested recently.

Screen Supplier to sell

„FAZ“ reports about the start of a trade sale of Cynora, a portfolio company of MIG Fonds.